Edaravone prevents Fas-induced fulminant hepatic failure in mice by regulating mitochondrial Bcl-xL and Bax

Shock
Takeshi MiyasouYasuo Kamiyama

Abstract

Fulminant hepatic failure is a serious disease that has a poor cure rate unless liver transplantation is performed. Edaravone, a free radical scavenger, has been approved for the treatment of acute cerebral infarction, and its mechanism of action involves scavenging free radicals generated in ischemic tissues. We assessed the ability of 3-methyl-1-phenyl-2-pyrazolim-5-one (edaravone) to prevent Fas-induced acute liver failure in mice and examined the mechanisms underlying the observed effects. BALB/c mice were administered 0.25 microg/g (i.v.) body weight of a purified hamster agonist anti-Fas monoclonal antibody (clone Jo2). The mice also received either edaravone or isotonic sodium chloride solution before or after Jo2 treatment. Edaravone improved the survival rate of the mice markedly. Histopathological findings and serum aspartate aminotransferase levels showed that edaravone reduced the degree of liver injury caused by Jo2. Terminal deoxynucleotidyl transferase-mediated 2'-deoxyuridine 5'-triphosphate nick end labeling staining showed that edaravone reduced the number of apoptotic hepatocytes. Edaravone also prevented cytochrome c release and caspase 3 activity, recognized as markers of apoptosis after mitochondrial disru...Continue Reading

References

Sep 8, 1978·Science·I Fridovich
Nov 1, 1995·The Journal of Experimental Medicine·P R GalleL Runkel
Apr 1, 1995·Lipids·N A PorterK A Mills
Aug 26, 1993·Nature·J OgasawaraS Nagata
Jan 1, 1995·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J H HoofnagleN Ascher
Oct 28, 1994·Biochemical and Biophysical Research Communications·E MitaT Kamada
May 15, 1993·Lancet·D A Carson, J M Ribeiro
Dec 16, 1993·The New England Journal of Medicine·W M Lee
Dec 10, 1996·Proceedings of the National Academy of Sciences of the United States of America·J XiangS J Korsmeyer
Feb 7, 1997·Cell·S Nagata
May 2, 1998·The EMBO Journal·C ScaffidiM E Peter
Jun 22, 1999·Current Opinion in Immunology·C ScaffidiM E Peter
Mar 31, 2000·Experimental Cell Research·T S Zheng, R A Flavell
May 1, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Juan B MiñanaJuan Sastre
Jun 11, 2002·Gastroenterology·Jan B HoekJohn G Pastorino
Jun 21, 2003·American Journal of Physiology. Heart and Circulatory Physiology·Katare Gopalrao RajeshHironori Maeda
Sep 5, 2003·The Journal of Pharmacology and Experimental Therapeutics·Hiroshi KonoYoshiro Matsumoto
Jul 19, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Xiaodong WangArthur I Cederbaum

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis